Novel Targeted Therapies in Hematologic Malignancies

Review expert perspectives on key findings on novel targeted therapies in hematologic malignancies presented at the 2017 ASH annual meeting.

Share

Supporters

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology